TD Cowen analyst Marc Frahm has maintained their bullish stance on RVMD stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Marc Frahm has given his Buy rating due to a combination of factors that highlight Revolution Medicines’ strategic advancements in pancreatic ductal adenocarcinoma (PDAC) treatment. The company is making significant progress with its daraxonrasib trials, including the RASolute302, which is nearing enrollment completion, and the initiation of RASolute303 and RASolute304 trials. These efforts are aimed at establishing daraxonrasib as a global standard of care across various PDAC lines, offering a substantial market opportunity.
Additionally, Revolution Medicines is exploring further potential with zoldonrasib, particularly in first-line G12D+ PDAC, with plans for a pivotal trial in 2026. Despite emerging competition, the management’s confidence in zoldonrasib’s leading position among G12D specific agents reinforces the company’s robust pipeline. These developments, along with the company’s strong financial position, underpin Frahm’s optimistic outlook and Buy rating for Revolution Medicines.
In another report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $104.00 price target.